Congress Publications

Abivax’s lead drug candidate, obefazimod (originally known as ABX464), is an investigational drug candidate that has not yet been approved for commercial use in any jurisdiction, but it has already garnered plenty of attention in the industry. The following collection of congress publications are from medical meetings, beginning in 2026.

The information on this website is intended for healthcare professionals only. It may contain scientific content and medical data not suitable for the general public. Obefazimod is an investigational agent not approved for use by any health regulatory agencies in any indication. By proceeding, you confirm that you are a licensed healthcare professional.

European Crohn’s and Colitis Organization (ECCO) 2026

Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease | PRESENTATION

S Danese,  F Magro,  B Siegmund,  R Atreya,  J Santo,  A Garcel,  S D’Alessio,  M Pehrsson,  J Mortensen,  M Sorokina Alexdóttir,  A C Bay-Jensen,  M A Karsdal,  R Mosig,  C Rabbat,  M de la Rosa,  F Cataldi,  B Verstockt
Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials | PRESENTATION

B Siegmund,  R Atreya,  F Cataldi,  D Jacobstein,  J Santo,  C Rabbat,  K Shan,  P Miheller,  C Gilletta de Saint Joseph,  B G Wojnarska,  B Verstockt,  F Magro,  P Dulai
Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 Phase 3 trials | PRESENTATION

S Heeren,  P Dulai,  B Neneman,  B Bunganič,  J Pumprla,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  L Peyrin-Biroulet
Improvements in patient-reported, disease-specific and overall quality-of-life among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials | PRESENTATION

F J Baert,  R Atreya,  L Mihalkanin,  P Korga,  M Fedurco,  U Seidler,  X Tretón,  C Rabbat,  J T Fine,  K Shan,  C M Dolan,  D Jacobstein,  F Cataldi,  B E Sands
Impact of baseline disease duration on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3 trials | PRESENTATION

G D’Haens,  D T Rubin,  R Kempinski,  J Kiełtucki,  J V Baláz,  D Laharie,  A Armuzzi,  X Tretón,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  A Yarur
Improvements in patient-reported fatigue among patients with moderately to severely active UC treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 trials | PRESENTATION

M C Dubinsky,  S Danese,  D T Rubin,  B E Sands,  M Gregus,  A Armuzzi,  G D’Haens,  U Seidler,  X Tretón,  C Rabbat,  J T Fine,  K Shan,  C M Dolan,  D Jacobstein,  F Cataldi,  B Siegmund
Impact of concomitant corticosteroid use on efficacy and safety of obefazimod at week 8 in moderately to severely active UC | POSTER

X Tretón,  M C Dubinsky,  U Seidler,  L Jonaitis,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  F D’Amico,  S Lee,  D T Rubin
Pooled analysis of efficacy and safety of once-daily oral obefazimod in North American patients from the ABTECT Phase 3 induction trials | POSTER

B E Sands,  M C Dubinsky,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  R Panaccione,  T E Ritter,  J Siddiqui,  G A Duvall,  P Dulai
Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials | POSTER

U Seidler,  S Danese,  L Peyrin-Biroulet,  M C Dubinsky,  R Atreya,  A Armuzzi,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  D Laharie,  P Dulai,  D T Rubin,  B E Sands
Improvements in patient-reported bowel urgency and nocturnal bowel movements among patients with moderately to severely active UC treated with obefazimod induction therapy | POSTER

M C Dubinsky,  S Danese,  D T Rubin,  M P Sparrow,  T Hlavaty,  F Magro,  S Nancey,  C Rabbat,  J T Fine,  K Shan,  C M Dolan,  D Jacobstein,  F Cataldi,  A Armuzzi
Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active UC | POSTER

R Atreya,  B E Sands,  D T Rubin,  M C Dubinsky,  A Armuzzi,  X Tretón,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  T Hlavaty,  R Witek,  P Dulai,  S Danese
Continued efficacy improvement beyond induction with once-daily obefazimod: week 8–48 outcomes from the Phase 2b open-label maintenance study, stratified by prior advanced-therapy exposure | POSTER

A Armuzzi,  S Danese,  R Atreya,  M C Dubinsky,  B E Sands,  P Dulai,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  D T Rubin
Obefazimod enhances miR-124 expression in blood and colon tissue and reduces IL-17A and IL-6 in serum of patients with moderate-to-severely active UC | POSTER

B Siegmund,  S Danese,  M C Dubinsky,  R Atreya,  A Abecassis-Borgus,  C Apolit,  J Sandri,  C Belda,  P Amin,  J Santo,  R Mosig,  D Jacobstein,  F Cataldi,  C Rabbat,  S Howaldt,  B Verstockt,  G D’Haens,  P Dulai
Impact of prior inadequate response to advanced therapy (ATIR) on the efficacy of obefazimod in patients with moderately to severely active UC | POSTER

F J Baert,  D T Rubin,  L Wolanski,  H Toeroek,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  A de Sa Rolim,  F D’Amico,  B E Sands
Impact of prior advanced therapy inadequate response by drug class on symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled analysis of ABTECT Phase 3 induction trials | POSTER

S Danese,  B E Sands,  S Heeren,  R Schnabel,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  M Gregus,  M P Sparrow,  D T Rubin
Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active UC | POSTER

F Magro,  B E Sands,  S Danese,  M C Dubinsky,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  L Harlacher,  F Scaldaferri,  G D’Haens,  L Biedermann,  L Peyrin-Biroulet
Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials | POSTER

A Armuzzi,  R Atreya,  M P Sparrow,  S Markovic,  C Le Berre,  T Hlavaty,  X Tretón,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  M C Dubinsky
Improvements in patient-reported work productivity and activity impairment among patients with moderately to severely active UC treated with obefazimod induction therapy | POSTER

H Tilg,  P Dulai,  S Skybalo,  V Neshta,  S Howaldt,  F D’Amico,  M Gregus,  C Rabbat,  J T Fine,  K Shan,  C M Dolan,  D Jacobstein,  F Cataldi,  B Siegmund
Impact of baseline Mayo endoscopic subscore on the efficacy of once-daily oral obefazimod in moderately to severely active UC | POSTER

L Peyrin-Biroulet,  B E Sands,  A Armuzzi,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  H Toeroek,  S Nancey,  G D’Haens,  D Laharie,  M C Dubinsky
Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active UC | POSTER

D T Rubin,  M C Dubinsky,  F Scaldaferri,  F Cataldi,  D Jacobstein,  C Rabba,  K Shan,  O Ramos Junior,  O Leoshyk,  A de Sa Rolim,  Y Bouhnik,  R Atreya
Impact of age on the efficacy and safety of once-daily oral obefazimod in moderately to severely active UC | POSTER

F Magro,  H Tilg,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  S Nancey,  S Markovic,  R Rocco,  L Harlacher,  A Yarur
Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3 induction trials | POSTER

F Scaldaferri,  U Seidler,  X Tretón,  F D’Amico,  A Armuzzi,  S Howaldt,  S Heeren,  R Atreya,  F J Baert,  H Tilg,  F Cataldi,  D Jacobstein,  C Rabbat,  K Shan,  M Cicala